Background: Metronidazole is the most commonly used antimicrobial for Bacteroides fragilis infections and is recommended for prophylaxis of colorectal surgery. Metronidazole resistance is increasing and the mechanisms of resistance are not clear.
Introduction
Bacteroides fragilis is an anaerobic commensal that, along with other Bacteroides species, performs vital functions in the human gastrointestinal tract, including energy harvesting, bile acid recycling, development of the host immune system 1,2 and providing protection from inflammation by inducing a subset of T cells that secrete the anti-inflammatory cytokine interleukin-10. 2 However, if B. fragilis moves out of its niche in the gut, it can cause serious, and potentially fatal, infections in humans; it is the most frequently isolated anaerobic bacterium from patients with deep tissue infections, intra-abdominal infections, bacteraemia, abscesses and endocarditis. 1, 3, 4 Metronidazole is the most commonly used drug worldwide to treat infections involving B. fragilis 5, 6 and has been the treatment of choice for surgical prophylaxis (e.g. for colorectal surgery) for almost 40 years. 7, 8 Levels of metronidazole resistance in Bacteroides species had remained remarkably low, but recently there has been a gradual trend in increased resistance that may relate to increasing use of metronidazole for other infections. For example, metronidazole use has widened to include treatment of Clostridium difficile infection 9 and eradication regimens for Helicobacter pylori. 10 A worrying development is the report of multidrug-resistant isolates and treatment failure. potential spread of resistance as well as options for drug development.
Metronidazole is a prodrug and its cytotoxicity depends on the reduction of the nitro group to a toxic nitro anion radical, which may cause DNA damage and/or indirectly interfere with the redox system of the microbe. The redox environment of anaerobic bacteria facilitates the activation of the prodrug to its toxic form. Reduction of metronidazole both activates it and creates a concentration gradient, driving further drug uptake and therefore increases the concentration of the toxic intermediates.
14 Understanding the mechanisms of activation and action of metronidazole, as well as resistance to metronidazole, has been the subject of study in the past several years. This has included detailed investigation of metronidazole activity in Helicobacter species and protozoan organisms in addition to anaerobic bacteria. 15 Despite this, the exact mode of transforming the non-toxic prodrug to the toxic freeradical intermediate is not completely clear, although the redox system of the target microbe is known to be involved. The very low redox potential of metronidazole limits possible electron donors. In anaerobes, ferredoxin-like Fe-S proteins have a lower redox potential; thus, the pyruvate:ferredoxin oxidoreductase (PFOR) system has formed the basis for current models of metronidazole activation. Evidence for this model includes observed increases in metronidazole resistance with down-regulation of pyruvate oxidoreductase via metabolic shift to the conversion of pyruvate into lactate via dehydrogenase rather than pyruvate oxidoreductase. 16 More recent data in Trichomonas suggest a second, non-PFOR, flavin-based mechanism of metronidazole activation, 17 in which the flavin enzyme thioredoxin reductase reduces metronidazole and is not dependent on the iron status of the cell. Reactive metabolites of metronidazole can then form covalent adducts with thioredoxin reductase and other proteins that are known or assumed to be associated with thioredoxin-mediated redox regulation (ribonucleotide reductase, thioredoxin peroxidase and cytosolic malate dehydrogenase).
Metronidazole resistance mechanisms in B. fragilis are also complex. There is a requirement for activation and any alteration in metabolic activity that prevents or reduces activation can increase resistance. 16 Also, antimicrobial action can cause DNA damage and mutations that result in improved DNA repair can increase resistance. 18, 19 Additionally, some B. fragilis strains produce a 5-nitroimidazole reductase (Nim) that converts the nitro group of metronidazole into the non-toxic amine derivative. 6, 20 Several different nim genes (nimA -H) have been reported for B. fragilis and a novel nim gene (nimJ) that is not recognized by the 'universal' nim primers was reported recently. 21 It is possible that reported 'nim-negative' clinical isolates contain a functional nim gene that is unrecognizable by the published 'universal' primers, but it is also clear that metronidazole resistance can be nonnim based. Our research and that of others indicates that non-nim-based mechanisms are important in clinical levels of resistance to metronidazole. For example, nimJ and nimE, from two different metronidazole-resistant clinical isolates, could confer increased metronidazole to BF638R, but not to the MIC levels seen in the clinical isolate. 21 Several nim-negative, metronidazoleresistant B. fragilis strains have been reported 22 and metronidazole resistance is also inducible in the metronidazole-susceptible type strain B. fragilis NCTC 9343. 23 If mutated, in addition to the PFOR system, genes involved in the regulation of sugar catabolism, 16 resistance -nodulation -division family Bacteroides multidrug efflux (bme) pumps 24 and DNA repair 18, 19, 25, 26 can impact Bacteroides metronidazole susceptibility. This study demonstrates that mutation in an iron transport protein, feoAB, generated by transposonmediated gene disruption, enhances metronidazole resistance and provides evidence of the key role of intracellular iron in susceptibility to metronidazole.
Methods

Strains and culture conditions
All feoAB constructs were derived from BF638R (Table 1) . Primers used in the construction of specific mutants are listed in Table S1 (available as Supplementary data at JAC Online). The specific construct used in each experiment is described below. Bacterial strains were grown at 378C as described previously 24 using brain heart infusion (BHI) media supplemented with 15 mg/L haemin (BHIS) for B. fragilis isolates in H. M. Wexler's laboratory (Anaerobe Systems, Morgan Hill, CA, USA) or BHI supplemented with 1 g/L L-cysteine, 5 mg/L haemin, 1 mg/L resazurin and 20 mL/L 10% NaHCO 3 (BHIS-ER) in E. R. Rocha's laboratory and Luria -Bertani agar or broth (Sigma) for Escherichia coli DH10B. The concentration of haemin used in different laboratories is above the minimum required for B. fragilis growth. 27 For some experiments, bacteria were grown in semi-defined medium (SDM) as described previously. 28 Addition of 50 mM 2,2 ′ -bipyridyl was used to restrict iron availability in SDM. Ferrous sulphate at 100 mM was added for high-iron growth conditions. 28 Bacteroides isolates were incubated in anaerobic jars (Anoxomat, 5% CO 2 , 5% H 2 and 90% N 2 ) or in an anaerobic chamber (10% CO 2 , 10% H 2 and 80% N 2 ). E. coli was incubated in ambient air at 378C. Ampicillin (50 mg/L), erythromycin (10 mg/L), rifampicin (10 mg/L), gentamicin (25 mg/L) and kanamycin (40 mg/L) were used for selection as indicated.
MIC determination
MICs were determined using Etest strips (bioMérieux, Durham, NC, USA). 21 
Molecular methods
DNA preparation, restriction digestions, gel electrophoresis and analysis were done as described previously. 24 
Generation of metronidazole-resistant transposon mutants
A BF638R transposon mutant pool (50 000 isolates) was generated using the mariner transposon-based vector pSAM-Bt 29 as described previously 30 and stored at 2808C. For the isolation of metronidazole-resistant mutants, 50 mL from the transposon mutant pool (2.9×10 6 cfu) was plated onto BHI agar plates containing 0.5 mg and 1 mg/L metronidazole, respectively (MIC of metronidazole for BF638R is 0.2 mg/L). The plates were incubated at 378C for 2 -3 days under anaerobic conditions. Following incubation, 40-50 colonies appeared on each plate and 32 (8 randomly selected from each plate) were chosen for further study.
Identification of transposon-disrupted genes
The transposon-disrupted genes were identified by semi-random primer PCR as described previously. 30 
Deletion of BF638R_1421 in BF638R
Approximately 500 bp of upstream and downstream sequence of BF638R_1421 was PCR amplified (upstream primers, 638R_1421 UpF/638R_1421 ermF JoinR; downstream primers, 638R_1421 ermF Join F/638R_1421 UpR, Table S1 ), fused to an erm(F) cassette amplified with primers 638R_1421 erm(F)F and 638R_1421 erm(F)R (Table S1 ) by overlapping PCR and cloned into the suicide vector pGB909 31 to generate pGB909 [d638R_1421 Up-erm(F)F-Do]. The generated suicide vector was used to replace BF638R_1421 with erm(F) in BF638R by homologous recombination and the deletion was verified by PCR with primers 638R_1421 More upF/638R_1421 More DoF (Table S1 ) and sequencing.
Two independently derived strains of the resulting erm(F) R mutants (biological replicates) were chosen for further study (BF638RDfeoAB-A and BF638R DfeoAB-B). Also, two separate transposon mutants with mutations in the feoA region (BF638R VfeoA-MET14) and feoB region (BF638R VfeoB-MET1) of BF638R_1421, respectively, were used in MIC determinations.
Construction of feoAB insertional mutant
A 725 bp internal N-terminus fragment of BF638R_1421 was PCR amplified with primers FeoAB1-Forward and FeoAB1-Reverse (Table S1 ) and cloned into the pGEM-T vector (Promega, Madison, WI, USA). An SphI/SacI fragment containing the feoAB internal region was then cloned into the SphI/SacI sites of the suicide vector pFD516. 32 The new construct, pER-1, was mobilized from E. coli DH10B into BF638R by a triparental filter mating protocol. 32 Transconjugants were selected on BHIS agar containing 20 mg/L rifamycin, 100 mg/L gentamicin and 10 mg/L erythromycin. PCR analysis was used to confirm the insertion of pER-1 into the BF638R chromosome. A transconjugant, BER-1, containing the feoAB::pFD516 construct inserted into the BF638R chromosome was selected for further studies.
Isolation of a feoAB::pFD516 revertant to the wild-type feoAB gene
The BER-1 strain was grown in BHIS-ER broth through five consecutive passages in the absence of erythromycin. An aliquot of the culture was then used to inoculate iron-limiting SDM supplemented with haemin as described previously to allow for the enrichment of the culture with revertants of single cross-over back to wild-type genotype. 28 After a second passage in the same fresh medium, the culture was plated onto BHIS-ER agar. Fifty colonies were picked up and spotted onto two sets of BHIS-ER plates (one plate containing rifamycin, gentamicin and erythromycin and a second plate containing rifamycin and gentamicin only). Erythromycin-susceptible colonies were selected and the reversion of the feoAB allele to wild-type was confirmed by PCR amplification with primers FeoAB-operon-2Forward and FeoAB-operon-2Reverse and sequencing with primers FeoAB1-Forward and FeoAB1-Reverse (Table S1 ). The strain was designated BER-54. 28 Construction of a feoAB::b-xylosidase (xylB) transcriptional fusion reporter gene A furA deletion mutant was constructed as described previously. 33 A feoAB::b-xylosidase reporter gene in a feoAB mutant background was constructed by cloning a 1.3 kb promoterless b-xylosidase/a-arabinosidase bifunctional reporter gene 34 into the EcoRI site of pER-1. The new construct, pER-4, was mobilized into the BF638R parent strain and the furA deletion mutant, BER-2, 33 as described above. The new constructs, Veeranagouda et al.
BER-17 (BF638R feoAB::xylB) and BER-18 (BF638R DfurA feoAB::xylB), were used for transcriptional analysis of the feoAB gene under iron-replete and iron-limiting conditions.
Enzyme assays
b-Xylosidase assays in crude extracts of bacteria grown in SDM under ironreplete and iron-limiting conditions (bipyridal used to limit iron) were performed as described previously in detail. 28 
Construction of a feoAB deletion mutant strain
To construct the feoAB deletion mutant, a 1.876 kb internal DNA fragment from feoAB was deleted and replaced by the tetracycline resistance gene tetQ. Briefly, a 1.615 kb chromosomal fragment upstream of BF638R feoAB (BF638R_1421), including the first 70 nt within the N-terminus region, was amplified by PCR using primers FeoAB-BamHI-Forward and FeoAB-BglII-Reverse (Table S1 ). The amplified DNA fragment was cloned into the unique BamHI site of the E. coli-Bacteroides shuttle suicide vector pFD516 32 containing a 2.6 kb tetracycline tetQ resistance cassette in the BamHI/SstI site. Subsequently, a 1.791 kb fragment downstream from feoAB, containing the last 546 nt of the C-terminus region, was amplified by PCR using primers FeoAB-SstI-Forward and FeoAB-SstI-Reverse (Table S1 ). The amplified fragment was cloned into the unique SstI site of the new construct pER-66. The plasmid pER-66, containing the DfeoAB::tetQ construct, was mobilized from E. coli DH10B into BF638R by triparental filter mating protocols as described above. Transconjugants were selected on BHIS-ER agar containing 20 mg/L rifamycin, 100 mg/L gentamicin and 5 mg/L tetracycline. Determination of susceptibility to either tetracycline or erythromycin was carried out to identify recombinants that were tetracycline resistant and erythromycin susceptible. Southern blot analysis was used to confirm the double cross-over genetic allele exchange of pER-66 into the BF638R chromosome. The new transconjugant, BER-51 (containing the DfeoAB::tetQ construct inserted into the BF638R chromosome), was selected for further studies.
Construction of a complementation vector for BF638R_1421
The B. fragilis expression vector pLYL101 35 was used for cloning the feoAB gene. To construct the complementation vector with a strong promoter, 102 nt of the promoter for the polysaccharide H (PSH) gene (i.e. upstream of BF9343_3376) was amplified using primers 9343 PmmVF PstI/ 638R_1421 P JoinR (Table S1 ). BF638R_1421 was amplified using primers 638R_1421 P JoinF/638R_1421 SphIR (Table S1 ). The two amplicons were stitched by overlapping PCR. The resulting PCR product was digested with PstI/SphI and ligated into PstI/SphI-digested pLYL101 and cloned into E. coli Mach1 (NEB). The resulting vector, pLYL101-BF638R_1421, was mobilized into BF638R by triparental mating of E. coli/pLYL101::PSH promoter-BF638R_1421, BF638R and E. coli-pRK231 helper as described previously. 21 A second complementation vector for feoAB was separately constructed in the BER-51 strain. Briefly, a 2833 bp DNA fragment containing 225 bp upstream of the feoAB ATG start codon and 125 bp downstream of the stop codon was PCR amplified from BF638R using primers FeoAB-operon2Forward and FeoAB-operon-2Reverse, designed to incorporate BamHI and BglII sites, respectively (Table S1 ). The PCR-amplified fragment was cloned into the BamHI site of the shuttle vector pFD288. 32 Automated nucleotide sequencing was used to confirm the native feoAB gene in the new construct pER-191. pER-191 was mobilized into BER-51 by triparental mating as described above. Transconjugants were selected on BHIS-ER agar containing 20 mg/L rifamycin, 100 mg/L gentamicin, 5 mg/L tetracycline and 10 mg/L erythromycin. The new strain, BER-125 (BF638RDfeoAB::tetQ feoAB + ), was used for genetic complementation analysis.
Measurement of transcription levels by quantitative (q) RT-PCR
Transcription levels of selected genes were determined using qRT -PCR. Total RNA for qRT-PCR was prepared from early to mid-log growth strains (OD 600 0.6-0.8) grown in BHIS using the RNAeasy mini kit with RNAprotect (Qiagen, CA, USA). Contaminating DNA was removed with the RNase-free DNase Set (Qiagen, CA, USA). qRT-PCR studies were done using SYBR Green RT-PCR Mix (Applied Biosciences, CA, USA or Bio-Rad Laboratories) and the StepOnePlus instrument (Applied Biosciences, CA, USA) or the iCycler (Bio-Rad Laboratories). The primers used for qRT -PCR analysis are listed in Table S2 (available as Supplementary data at JAC Online). The comparative C T (DDC T ) method was used to determine the relative transcription levels using 16S RNA as the endogenous control. The analysis program is part of the StepOne software.
Global transcriptome analysis
Bacteria were grown in BHIS to mid-log growth (OD 600 0.8-1) and RNA was prepared from cells using the Qiagen RNeasy Kit (Qiagen, CA, USA) according to the manufacturer's instructions. rRNA was removed using the Ambion Microbe Express Kit (Life Technologies). cDNA was prepared using the Invitrogen Superscript Kit (Life Technologies) and quantified by RNA-Seq analysis (Otogenetics, Norcross, GA, USA). RNA-Seq files were analysed using the Lasergene Genomics Suite (DNASTAR, Madison, WI, USA).
In vitro growth measurements
In vitro growth of BF638R and BF638R BER-1 feoAB 2 were measured in defined minimal medium 36 and in BHI broth (37 g/L, Oxoid) supplemented with haemin (0.5 mg/L) and cysteine hydrochloride (0.5 g/L). The culture medium also contained appropriate antibiotic for selection purposes. At least two growth rate experiments were carried out for each strain of BF638R analysed in both defined medium and supplemented BHI, with total viable counts taken at various timepoints.
In vivo growth measurements
In vivo growth of BF638R, BF638R/pDF340 and BF638R BER-1 feoAB 2 was examined using a mouse chamber model of peritoneal infection as described previously. 37, 38 Briefly, two chambers containing live bacterial suspension, bound at either end with 0.45 mm pore nitrocellulose membrane filters (Millipore), which allow the influx of soluble host factors but not mouse cells and preclude the efflux of bacterial cells, were implanted in the mouse peritoneal cavity after surgical incision; the surgical wound was then sutured. In this model, bacteria are grown in vivo without causing peritoneal infection. After the required incubation time, mice were sacrificed (at least two mice per timepoint), the chambers removed and the total viable count determined by serial dilution and agar plating. The experiments were licenced by the Department of Health, Social Services and Public Safety Project and Personal Licenses and carried out in accordance with the UK Animals (Scientific Procedures) Act 1986. B. fragilis pDF340 was used as a positive control for BF638R BER-1.
Results
Metronidazole resistance is linked to disruption of a putative iron transport gene feoAB (BF638R_1421)
Of the metronidazole-resistant transposon mutants generated using the transposon vector mutant, 30 32 were selected at random and restreaked onto BHI agar containing 1 mg/L metronidazole. All of these mutants had transposon insertions in BF638R_1421, a putative transmembrane ferrous transport fusion protein gene (Figure 1) . Nine of the 32 mutants had unique feoAB linked to metronidazole resistance in B. fragilis 2637 JAC insertion positions. In addition, in a separate study, continuous subculture of B. fragilis NCTC 9343 in the presence of sub-MIC concentrations of metronidazole generated nonsense mutations in feoAB (F. Husain, Y. Veeranagouda and H. M. Wexler, unpublished data). Insertion and deletion mutants in BF638R feoAB also exhibited metronidazole resistance. The MIC of metronidazole for BF638R is 0.2+0.05 mg/L; all 32 mutants grew well on plates containing 1 mg/L metronidazole. Comparison of MICs for feoAB-deficient strains with those for wild-type BF638R showed that metronidazole MICs for strains lacking feoAB were 10-times higher than for BF638R ( Table 2 ). The feoAB transposon mutants were disrupted in either the feoA or feoB region, but both had similar levels of metronidazole resistance. Genetic complementation of feoAB deletion mutant BER-51 restored the metronidazolesusceptible phenotype (e.g. BER-125) ( Table 2) . Also, subculture of BER-1 (insertional feoAB mutant) in the absence of the inserted antibiotic marker selection enabled the isolation of wild-type metronidazole-susceptible revertants (e.g. BER-54) from ironlimited defined medium ( 
BF638R_1421 encodes a FeoAB transport protein
The predicted amino acid sequence of BF638R_1421 (827 amino acids) was examined for conserved domains at the Conserved Domains Database (http://www.ncbi.nlm.nih.gov/Structure/cdd/ wrpsb.cgi). The protein sequence of BF638R_1421 contained regions matching all of the conserved domains of the FeoA and FeoB proteins of E. coli (Figure 1, upper panel) . 39 In comparison, the E. coli Feo complex is composed of three proteins: FeoA, B and C. FeoA is a small SH3 domain-containing protein and mediates protein -protein interactions. FeoB is a large protein composed of a hydrophobic N-terminal G-protein domain, which has GTPase activity, and a C-terminal integral membrane domain predicted to consist of eight transmembrane a-helices that form two 'gates'. 40 FeoC is a small regulatory protein. In BF638R, the feoA and feoB open reading frames are fused in-frame, resulting in a predicted FeoA -FeoB hybrid protein ( Figure 1 ) and there is no adjacent feoC gene. The conserved domains in BF638R_1421 are the SH3 domain of FeoA (amino acids 1-75), the hydrophilic G-protein region (amino acids 115 -273) and the two gate motifs (amino acids 507-603 and 636-798). A similar FeoA -FeoB fusion protein is found in the Feo1 system of Porphyromonas gingivalis and has been shown to be involved in ferrous iron uptake. 41 Thus, BF638R_1421 is a FeoAB hybrid protein and is probably involved in ferrous iron uptake in BF638R. Comparison with the Artemis Comparison Tool 42 and BLAST analysis indicated that BF638R_1421 is conserved in the type strain NCTC 9343 (99% identity to BF1353) and B. fragilis YCH46 (99% identity to BF1417). The adjacent genes are also conserved.
Growth of BER-1 (BF638R feoAB::pFD516) is attenuated in medium without supplemental ferrous iron compared with BF638R/pFD340
The doubling time of BER-1 in vitro is 8.59 h in defined medium and 2.64 h in BHIS-ER, which is 2-4-fold higher than that of (Table 3) . Moreover, the growth of BER-1 is reduced in SDM under low-iron conditions but not under high-iron conditions compared with the parent strain (E. R. Rocha and C. J. Smith, unpublished data). These results validate the importance of the FeoAB uptake system in B. fragilis and confirm previous studies showing that B. fragilis requires both inorganic iron and haem iron for maximum growth. 27 The growth of the feoAB-deficient strains in BHI broth or BHIS agar, although slower than the wildtype, indicates that disruption of BF638R_1421 does not affect the normal physiology of the cells when iron is plentiful, suggesting that other iron uptake mechanisms exist. In contrast, the growth rate of BER-2 (BF638R DfurA) was similar to wild-type BF638R (Table 3) .
Overexpression of feoAB appears to be toxic in B. fragilis feoAB-deficient mutants BF638R_1421 (feoAB) was cloned into the B. fragilis expression vector pLYL101 and transformed into E. coli; the clone was verified by sequencing. Despite several attempts to introduce it back into BF638R DfeoAB by triparental mating to complement the deletion, a clone with an intact gene could not be isolated. A few transformants were isolated, but the gene sequence of feoAB on the expression plasmid had been disrupted by sequence rearrangements, suggesting that overexpression of feoAB on pLYL101 is toxic to BF638R.
In contrast, when the native feoAB gene in pER-191 was mobilized into the feoAB deletion mutant BER-51, metronidazole susceptibility in the complemented strain, BER-125, was restored to the levels of the parent strain. Taken together, these data suggest that the transcription level of feoAB needs to be regulated by its own normal regulatory mechanisms and that overexpression seems to be toxic to the cell.
Genes implicated in spontaneous metronidazole resistance were not down-regulated
Earlier studies had demonstrated diminished expression, and in some instances transcription, of several genes in spontaneous metronidazole-resistant mutants, 23 including tpx (thioredoxin peroxidase), bfr (bacterioferritin), fldA (flavodoxin) and nifJ (aka porA; pyruvate:flavodoxin oxidoreductase). Therefore, transcription levels of these genes were measured in the metronidazoleresistant BF638R DfeoAB using qRT-PCR analysis. No changes in transcription levels of tpx (BF638R_2372), bfr (BF638R_3305), fldA (BF638R_2696) and nifJ (BF638R_3194) between BF638R and BF638R DfeoAB were seen, indicating that diminished transcription of these genes is not responsible for the observed metronidazole resistance of BF638R DfeoAB.
Transcription levels of typical iron stress-related genes were not increased
A defect in FeoAB might result in lowered iron transport and iron stress. Therefore, transcription levels of iron starvation-related genes in BF638R DfeoAB were measured. In E. coli, Fe 2+ starvation induces bfd (ferredoxin) and represses ftnA (Fe storage) expression. 43 The iron uptake regulator (fur) is also induced during Fe 2+ starvation in H. pylori. 44 Since FeoAB is an iron transporter, the effect of feoAB disruption on the transcription of genes that are known to be altered during iron starvation was measured. qRT -PCR analysis showed no difference between wild-type BF638R and BF638R DfeoAB in expression of nifJ (BF638R_3194), furA (BF638R_3276 and BF638R_3026), ftnA (BF638R_2891) and ferredoxin (BF638R_1702) genes (data not shown). Therefore, it appears that disruption of BF638R_1421 does not induce the typical response to iron starvation in BF638R. Thus, it is likely that in an iron-rich medium such as BHI, another mechanism for obtaining iron becomes operative and provides adequate iron to avert iron stress but insufficient intracellular iron to confer wild-type levels of metronidazole susceptibility.
Global transcriptome changes between BF638R and BF638R DfeoAB
Global transcriptome changes between BF638R and BF638R DfeoAB were determined. RNA-Seq analysis showed down-regulation of several dehydrogenase/oxidoreductase genes in BF638R DfeoAB. Among them, a putative dehydrogenase/oxidoreductase (BF638R_1133; nifJ) was down-regulated .12-fold in BF638R DfeoAB compared with BF638R (Table S3 , available as Supplementary data at JAC Online). In addition, nuoA -J, genes that code for respiratory complex I, 45 were also down-regulated by .2-fold in BF638R DfeoAB. The transcription levels of the genes BF638R_1133, BF638R_3326 (rdxA) and two genes, NADH-quinone oxidoreductase chain A and B (nuoA and nuoB), from the nuo operon (BF638R_0849 and BF638R_0850) were measured by qRT-PCR analysis in BF638R and BF638R DfeoAB (biological replicates A and B) and in six independent feoAB-transposon Mean of two independent growth curves. c Specific growth rate was calculated using Napierian logs and is expressed as h
21
. feoAB linked to metronidazole resistance in B. fragilis mutants. Transcription of BF638R_1133 was consistently ≥2-fold lower in BF638R DfeoAB compared with BF638R, but consistent down-regulation for the other genes was not seen.
feoAB transcription is regulated by iron in a Fur-dependent manner
The effect of Fur regulation on feoAB mRNA expression was investigated by measuring the levels of feoAB mRNA in BF638R and BF638R DfurA (BER-2) by qRT -PCR under high-iron and ironlimiting conditions (Figure 2a) . When BF638R was grown under high-iron conditions, repression of feoAB expression was observed, which switched to derepression under iron-limiting conditions. In BF638R DfurA (BER-2), however, the iron-mediated repression of feoAB transcription was no longer observed, indicating that FeoAB is controlled by Fur. The real-time RT-PCR determination of feoAB mRNA expression was confirmed by transcription fusion reporter b-xylosidase gene experiments in crude extracts of BER-17 (BF638R feoAB::xylB) and BER-18 (BF638R DfurA feoAB::xylB) grown under iron-replete and ironlimiting conditions. b-Xylosidase activity in strain BF638R feoAB::xylB was diminished under high-iron conditions compared with an 15-fold induction when grown under iron-limiting conditions. The b-xylosidase activity was no longer repressed in BER-18 (BF638R DfurA feoAB::xylB) under high-iron conditions compared with the levels of activity obtained under iron-limiting conditions (Figure 2b ).
Growth and survival of feoAB-and furA-deficient BF638R in vivo
The abilities of BF638R, BER-1 (BF638R DfeoAB), BF638R/pFD340 and BER-2 (BF638R DfurA) to survive and grow in an intraperitoneal abscess model 38 were compared ( Figure 3) . Reduction in the number of viable bacteria over time was observed until the number of viable bacteria was below detectable levels of 250 cells/mL after 21 days in the mouse peritoneal cavity. Growth of BER-1 and BER-2 were attenuated in the mouse intraperitoneal abscess model.
Discussion
Using an unbiased transposon mutagenesis procedure to generate a library of metronidazole-resistant mutants, 32 metronidazoleresistant mutants independently chosen for further study had a mutation in the iron uptake-associated feoAB gene. This indicates that mutation of feoAB is a favoured selection for evasion of metronidazole toxicity. Therefore, the effect of feoAB deletion on susceptibility to metronidazole was studied in more detail.
Although it is possible that the deficiency in feoAB might initiate a 'low-iron stress' response, altered transcription levels for putative genes involved in iron transport and uptake in the parent strain were not seen. Changes in the global transcriptome of the Veeranagouda et al.
feoAB-deficient strain were seen, but these could not be consistently repeated in qRT-PCR measurements, except for modest consistent down-regulation in BF638R_1133, a putative dehydrogenase/oxidoreductase. BF638R_3326, which codes for a nitroreductase, RdxA, was down-regulated in the RNA-Seq analysis but only variably down-regulated in the qRT -PCR analysis. BF638R_3326 and its homologue in H. pylori have been shown previously to contribute to metronidazole resistance in both BF638R and H. pylori.
5,23
Other studies did show alterations in metabolic and stress response pathways in spontaneous metronidazole-resistant mutants in nimnegative B. fragilis NCTC 9343. 23 Although protein expression varied somewhat in different growth phases, proteins with lowered expression (in one or more growth phases) included gadA, fkpA, tpx, bfr and fldA. PorA (nifJ) enzyme activity was severely diminished in mutants, but transcription levels were only modestly changed; the diminished activity could be attributed to mutations in the nifJ gene. 23 It seems clear that changes that result in metronidazole resistance may occur at many levels: mutation of the gene(s), transcription of the gene(s) or expression levels of the protein.
Our data demonstrate that feoAB mRNA expression is regulated by iron in a Fur-dependent manner and it is likely that B. fragilis Fur regulates other iron-regulated proteins that might be involved in metronidazole resistance. Interestingly, growth of BER-2 (BF638R DfurA) in an in vivo abscess model was attenuated, which suggests that Fur regulates genes required for survival within the peritoneal cavity. Down-regulation of several genes that might be regulated by a Fur-type regulator [oxido/nitro reductase genes, genes involved in the respiratory chain (e.g. nuo) and genes encoding putative TonB dependent outer membrane proteins] was seen in RNA-Seq analysis, although the changes were not always reproducible in qRT-PCR analysis. The changes may be extremely sensitive to growth phase or another unknown factor and this may be why the transcription level changes seen by Diniz et al. 23 in their studies could not be consistently duplicated in this study. It may be that additional Fur-like regulation is involved in these transcriptional level changes in response to the iron status of the cell.
While the exact manner in which the lack of FeoAB results in increased resistance to metronidazole cannot be pinpointed, it does appear that the lowered iron levels caused by the disruption of feoAB are the cause of the increased metronidazole MICs. It is not clear how cellular iron content affects metronidazole toxicity. One possibility is that PFOR activity towards activation of metronidazole is affected by iron. Another possible scenario is that the disruption of FeoAB results in an imbalance of intracellular iron homeostasis leading to deregulation of Fur-dependent or Fur-independent iron-regulated genes, which may have subsequent effects on the expression of redox pathways that affect either metronidazole activation or metronidazole toxicity. This would be similar to what is seen in Salmonella, where feoAB expression increases the level of Fur-Fe(II) that can then bind to its target promoters to repress transcription of various ironresponsive genes. 46 The fur system has also been implicated in metronidazole resistance in H. pylori. 47 Several induced mutations affecting H. pylori Fur's N-terminal arm increased metronidazole resistance, as did mutations affecting the region between DNA binding and dimerization domains. The authors concluded that fur mutations can affect susceptibility to metronidazole by altering the balance among Fur's several competing activities, affecting expression of genes that control cellular redox potential or elimination of bactericidal metronidazole activation products. 47 The FeoAB system plays an important role in ferrous iron uptake and is also important in pathogenic processes in E. coli and other pathogenic bacteria, especially under anaerobic/microaerophilic conditions. 39, 48 We found that BF638R DfeoAB (BER-1) was attenuated in its ability to grow in an intraperitoneal mouse model. Similarly, feoB mutants of E. coli and Salmonella are attenuated in their ability to colonize mouse intestines. 39 Overexpression of feoAB was not tolerated in BF638R, suggesting that iron uptake needs to be carefully regulated for optimum cell growth and function of B. fragilis. Also, disruption of feoAB did not result in growth deficiency in iron-rich media, yet the amount of iron taken up was not sufficient to abrogate the metronidazole resistance seen, further indicating that the precise levels of iron uptake will have profound effects on cell metabolic processes.
Since the ability to assimilate iron is an important virulence factor, it is perhaps unlikely that a defect in feoAB is a clinical mechanism for metronidazole resistance. We hypothesize that the metronidazole-induced reduction in virulence contributes to the efficacy of the antimicrobial action of metronidazole in infections and in prophylaxis. We have demonstrated that strains with feoAB gene disruptions are selected by metronidazole and that feoAB mutants are disabled with respect to virulence potential. This could also have played a part in the, to date, slow development of metronidazole resistance in B. fragilis. The reasons for the increasing rate of metronidazole resistance are still not clear. Increasing horizontal transfer of nim genes is a worrying factor, although the contribution of nim genes to the high metronidazole MICs seen for clinically resistant isolates is being questioned. In a recent study, no correlation was found between Nim levels and metronidazole MICs and no evidence was found that Nim proteins protect B. fragilis from metronidazole by sequestering the activated antibiotic. 49 We did find modest increases in metronidazole MICs when nimE or nimJ was introduced into BF638R on a multicopy expression plasmid. 21 It is possible that the high metronidazole MICs seen for clinically resistant isolates are due to a combination of resistance factors (both nim genes and other factors, including some that may not yet be described). Furthermore, it appears that these factors have the potential to override the heretofore slow rise in metronidazole resistance and, in this context, the growing global evidence of nim gene horizontal gene transfer 11 -13 is a particular cause for concern as it may lead to an acceleration in the incidence of metronidazole resistance in the near future. The data presented here indicate that the susceptibility of B. fragilis to metronidazole is dependent on the iron status of the cell, in which iron uptake by FeoAB plays a key role. This supports the hypothesis that an iron-dependent system such as PFOR is the operative mechanism for metronidazole activation in B. fragilis. Further analysis of the role of feoAB-and furAregulated genes and the effect of iron levels on the organism is needed to fully understand the functioning and significance of all aspects of this metronidazole resistance pathway.
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